Theravance Biopharma, Inc. reported significant financial improvements in its latest 10-Q filing for the third quarter of 2025, showcasing a total revenue of $19.99 million for the three months ending September 30, 2025, a 19% increase from $16.87 million in the same period last year. For the nine months ended September 30, 2025, total revenues reached $61.57 million, up 35% from $45.63 million in the prior year. The increase in revenue was primarily driven by higher sales from the Viatris collaboration agreement, which accounted for $54.07 million in the nine-month period, reflecting a 19% year-over-year growth.
The company also reported a net income of $3.62 million for the third quarter, a notable turnaround from a net loss of $12.70 million in the same quarter of 2024. For the nine-month period, net income was $44.87 million, compared to a loss of $40.89 million in the previous year. This improvement was attributed to a $75.14 million net gain on realized contingent milestone and royalty assets from the sale of TRELEGY royalties to GSK, which significantly bolstered the company's financial position.
In terms of operational developments, Theravance Biopharma has made strides in its product offerings, particularly with YUPELRI, which received regulatory approval in China in June 2025, triggering a $7.5 million milestone payment. The company is also eligible for additional sales and regulatory milestones totaling up to $205 million related to YUPELRI. As of September 30, 2025, the company reported cash and cash equivalents of $174.77 million, a substantial increase from $37.80 million at the end of 2024, largely due to the proceeds from the sale of TRELEGY royalties and milestone payments.
Theravance Biopharma's strategic focus remains on advancing its pipeline, particularly the investigational drug ampreloxetine for neurogenic orthostatic hypotension. The company is currently conducting a Phase 3 clinical study for this product, with top-line data expected in early 2026. The company’s employee headcount has also seen a slight increase, reflecting its ongoing commitment to expanding its operational capabilities.
Looking ahead, Theravance Biopharma anticipates that its cash reserves will be sufficient to fund operations for at least the next twelve months. The company remains focused on disciplined capital allocation and is exploring additional strategic alternatives to enhance shareholder value, although no specific transactions have been confirmed at this time. The outlook for the company appears positive, driven by its strong revenue growth and ongoing product development initiatives.
About Theravance Biopharma, Inc.
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines for respiratory and neurological conditions. Its key products include YUPELRI for COPD and investigational therapies like ampreloxetine for neurogenic orthostatic hypotension in MSA patients. The company leverages strategic partnerships, patent protections, and a diversified development pipeline to deliver innovative treatments and create shareholder value.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.